Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim + RFA in Refractory HCC
NCT01923233Phase 2Withdrawn
- Sponsor
- Mirror Biologics, Inc.
- Start
- Nov 2014
- Primary completion
- Jun 2015
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allostim in hepatocellular carcinoma (HCC), sponsored by Mirror Biologics, Inc.. Planned start Nov 2014; status: withdrawn.
02
Drugs
allostim
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01923233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01923233.